Acute porphyrias: Pathogenesis of neurological manifestations

Seminars in Liver Disease

Volumn 18, Issue 1, 1998, Pages 43-52

  Meyer, Urs A ^a,b   Schuurmans, Macé M ^a   Lindberg, Raija L P ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Mouse model of acute porphyria; Pathogenesis; Porphyric neuropathy

Indexed keywords

PORPHOBILINOGEN SYNTHASE;

ACUTE INTERMITTENT PORPHYRIA; ARTICLE; DATA ANALYSIS; ENZYME DEFICIENCY; HEME SYNTHESIS; HUMAN; MOLECULAR GENETICS; NERVE CELL; NEUROLOGIC DISEASE; NEUROTOXICITY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

EID: 0031890977     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007139     Document Type: Article

References (71)

1. Lindberg RL, Porcher C, Grandchamp B, et al. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nature Genetics 1996;12:195-199
2. Yeung Laiwah AC, Macphee G, Boyle P, et al. Autonomic neuropathy in acute intermittent porphyria. J Neurol Neurosur PS 1987;48:1025-1030
3. Blom H, Andersson C, Olofsson BO, et al. Assessment of autonomic nerve function in acute intermittent porphyria: a study based on spectral analysis of heart rate variability. J Int Med 1996;240:73-79
4. McEneaney D, Hawkins S, Trimble E, et al. Porphyric neuropathy - a rare and often neglected differential diagnosis of Guillain-Barré syndrome. J Neurol Sci 1993;114:231-233
5. Bont A, Steck AJ, Meyer UA. Die akuten hepatischen Porphyrien und ihre neurologischen Syndrome. Schweiz Med Wschr 1996; 126:3-14
6. Kupferschmidt H, Bont A, Schnorf H, et al. Transient cortical blindness and bioccipital brain lesions in two patients with acute intermittent porphyria. Annals Int Med 1995;123:548-600
7. Patience DA, Blackwood DHR, McColl KEL, et al. Acute intermittent porphyria and mental illness - a family study. Acta Psych Scand 1994;89:262-267
8. Bylesjö I, Forsgren L, Lithner F, et al. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia 1996;37:230-235
9. Erbslöh W. Zur Pathologie und pathologischen Anatomie der toxischen Polyneuritis nach Sulfonatgebrauch. Deutsche Zeitschrift Nervenhetlkunde 1903;23:197
10. Bonkovsky HL, Schady W. Neurologic manifestation of acute porphyria. Semin Liver Dis 1982;2:108-124
11. Yeung Laiwah AC, Moore MR, Goldberg A. Pathogenesis of acute porphyria. Q J Med 1987;241:377-392
12. Windebank AJ, Bonkovsky HL. Porphyric neuropathy. In. Dyck RJ, Thomas SK (eds): Saunders, Philadelphia. Peripheric neuropathy. 1992
13. Cavanagh JB, Mellick RS. On the nature of peripheral nerve lesions associated with acute intermittent porphyria. J Neurol Neurosur PS 1965;28:320-327
14. Hierons R. Acute intermittent porphyria. Postgrad Med J 1957; 43:605
15. Gibson JB, Goldberg A. The neuropathology of acute porphyria. J Path Bact 1956;LXXI:495-510
16. Mustajoki P, Seppälainen AM. Neuropathy in latent hereditary hepatic porphyria. Brit Med J 1975;2:310-312
17. Albers JW, Robertson WC, Daube JR. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve 1978;1:292-296
18. Flügel KA, Druschky KF. Electromyogram and nerve condition in patients with acute intermittent porphyria. J Neurol 1977;214: 267-279
19. Shanley BC, Percy VA, Neethling AC. Neurochemistry of acute porphyria. In. Doss M (ed): Porphyrins in human diseases. Karger, Basel, 1976
20. Pierach, C. A., Edwards PS Neurotoxtcity of δ-aminolevulinic acid and porphobilinogen. Exp Neurol 1978;62:810-814
21. Wehner JM, Marley RJ. Genetic differences in the effects of δ-aminolevulinic acid on seizure latency in mice. Exp Neurol 1986;94:280-291
22. Percy VA, Shanley BC. Porphyrin precursors in blood, urine and cerebrospinal fluid in acute porphyria. S Afr Med J 1977;52: 219
23. Edwards SR, Shanley BC, Reynoldson JA. Neuropharmacology of delta-aminolaevulinic acid I. Effect of acute administration in rodents. Neuropharmacology 1984;23:477-481
24. Edwards SR, Shanley BC, Reynoldson JA. Neuropharmacology of δ-aminolaevulinic acid. II. Effect of chronic administration in mice. Neurosci Lett 1984;50:169-173
25. Mustajoki P, Himberg JJ, Tokola O, et al Rapid normalization of antipyrine oxidation by heme in variegate porphyria. Clin Pharmacol Ther 1992;51:320-324
26. 14C]-δ-aminolevulinic acid in normal and porphyric human subjects. Clin Chem 1968;34:233-251
27. Meyer UA, J. SL, Rees CA, et al. Intermittent acute porphyria. Demonstration of defective porphobilinogen metabolism. N Engl J Med 1972;286 1277
28. Shimizu Y, Ida S, Naruto H, et al. Excretion of porphyrins in urine and bile after the administration of delta-aminolevulinic acid. J Lab Clin Med 1978;32:795-802
29. Loots JM, Becker DM, Meyer BJ, et al. The effect of porphyrin precursors on monosynaptic reflex activity in the isolated hemisected frog spinal cord. J Neur Transm 1975;36:71-81
30. Nicoll RA. The interaction of porphyrin precursors with GABA receptors in the isolated frog spinal cord. Life Sci 1976;19:521-526
31. Jordan P, Bagust J, Kelly M, et al A model tor acute intermittent porphyria: effects of 5-aminolaevulinic acid on ventral root activity in the hemisected hamster spinal cord. Molec Aspects Med 1990;11:53-54
32. Becker DM, Goldstuck N, Kramer S. Effect of delta-aminolaevulinic acid on the resting membrane potential of frog sartorius muscle. S A Med J 1975:1790-1792
33. Percy VA, Lamm MCL, Taljaard JJF. δ-aminolaevulinic acid uptake, toxicity and effect on [14C] δ-aminobutyric acid uptake into neurons and glia in culture. J Neurochem 1981;36:69-76
34. Gorchein A. δ-aminolaevulinic acid is not directly toxic to human spinal cord neurons in culture. Biochem Soc T 1989;17: 577-578
35. Müller WE, Snyder SH. δ-aminolevulinic acid: influences on synaptic GABA receptor binding may explain CNS symptoms of porphyria. Ann Neurol 1977;2:340-342
36. Brennan MJW, Cantrill RC. δ-aminolaevulinic acid is a potent agonist for GABA autoreceptors Nature 1979;280 514-515
37. Brennan MJW, Cantrill RC. δ-aminolaevulinic acid and amino acid neurotransmitters Mol Cell Biochem 1981;38:49-58
38. Becker D, Viljoen D, Kramer S. The inhibition of red cell and brain ATPase by δ-aminolaevulinic acid. Biochim Biophys Acta 1971;225:26-34
39. Puy H, Deybach J-C, Bogdan A, et al. Increased δ-aminolevulinic acid and decreased pineal melatonin production. J Clin Invest 1996;97:104-110
40. Puy H, Deybach J-C, Baudry P, et al. Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks. Life Sci 1993;53:621-627
41. A agonist, muscimol, in rat jejunal preparations. Pharmacol Toxicol 1991;69: 52-55
42. Monteiro HP, Bechara EJH, Abdalla DSP. Free radicals involvement in neurological porphyrias and lead poisoning. Mol Cell Biochem 1991;103:73-83
43. Hermes-Lima M, Castilho RF, Valle VGR, et al. Calciumdependent mitochrondrial oxidative damage promoted by 5-aminolevulinic acid. Biochem Bioph Res Comm 1992;1180:201-206
44. Demasi M, Penatti CAA, DeLucia R, et al The prooxidant effect of 5-aminolevulinic acid in the brain tissue of rats: implications in neuropsychiatrie manifestations in porphyrias. Free Radical Bio Med 1996;20:291-299
45. Bonkovsky HL, Tschudi DP, Collins A, et al. Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusion of hematin. Proc Natl Acad Sci USA 1971;62:2725-2729
46. Gorchein A, Webber R. δ-aminolevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin Sci 1987;72:103-112
47. Beckei DM, Kramer S, Viljoen JD. Delta-aminolevulinic acid uptake by rabbit brain cerebral cortex. J Neurochem 1974;23: 1019-1023
48. Riopelle RJ, Kennedy JC. Some aspects of porphyrin neurotoxicity in vitro. Can J Physiol Pharm 1984;60:707-714
49. Rank JM, Carithers, R., Bloomer J. Evidence for neurological dysfunction in end-stage protoporphyric liver disease Hepatology 1993;18:1404-1409
50. DeMatteis F, Ray RE Studies on cerebellar haem metabolism in the rat in vivo. J Neurochem 1982;39:551-556
51. Lamon JM, Frykholm BC, Hess RA, et al. Hematin therapy for acute porphyria. Medicine 1979;58:252-269
52. DeMatteis F, Zetterlund J, Wetterberg L. Brain 5-aminolaevulinate synthase. Developmental aspects and evidence for regulator role. Biochem J 1981;196:811-817
53. Litman DA, Correia MA. L-tryptophan: a common denominator of biochemical and neurological events of acute hepatic porphyria. Science 1983;222:1031-1033
54. Litman DA, Correia MA. Elevated brain tryptophan and enhanced 5-hydroxytryptamine turnover in acute hepatic heme deficiency clinical implications. J Pharmacol Exp Ther 1985;232: 337-345
55. Price JM, Brown RR, Peters HA. Tryptophan metabolism in porphyria schizophrenia and a variety of neurologic and psychiatric diseases. Neurology 1959;9:456-468
56. Bonkovsky HL, Healey JF, Lurie AN, et al. Intravenous hemealbumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pool. Am J Gastroenterol 1991;86:1050-1056
57. Wilkinson LO, Dourish CT. Serotonin and animal behaviour. In: Peroutka SJ (ed): Serotonin receptor subtypes: basic and clinical aspects Wiley-Liss, New York. 1991
58. Alhaider AA, Lei SZ, Wilcox GL Spinal 5-HT3 receptor-mediated antinociception: possible release of GABA. J Neurosci 1991;11 1881-1888
59. Hedge SS, Eglen RM. Peripheral 5-HT-4-receptors. FASEB J 1996;10:1398-1407
60. Anderson KE, Alvares AP, Sassa S, et al. Studies in porphyria; V: drug oxidation rates in hereditary hepatic porphyria. Clin Pharmacol Ther 1976;19:47-54
61. Birnie GG, McColl KEL, Thompson GG, et al. Antipyrine metabolism in acute hepatic porphyria in relapse and remission. Br J Clin Pharmacol 1987;23:358-361
62. Herrick A, McLellan A, Brodie MJ, et al. Effect of heme arginate therapy on porphyrin metabolism and mixed function oxygenase activity in acute hepatic porphyria. Lancet 1987;2:1178-1179
63. Tokola O, Mustajoki P, Himberg JJ. Haem arginate improves hepatic oxidative metabolism in variegate porphyria Br J Clin Pharmacol 1988;26:753-757
64. Mustajoki P, Mustajoki S, Rautio A, et al. Effects of heme arginate on cytochrome P450-mediated metabolism of drugs in patients with variegate porphyria and in healthy men. Clin Pharmacol Ther 1994;36:9-13
65. Goldberg A, Doyle D, Yeung-Laiwah AC Relevance of cytochrome C-oxidase deficiency to the pathogenesis of acute porphyria. Q J Med 1985;57:799
66. Herrick AL, Fisher BM, Moore MR, et al. Elevation of blood lactate and pyruvate levels in acute intermittent porphyria - A reflection of haem deficiency? Clin Chim Acta 1990;190:157-162
67. Brenner DA, Bloomer JR. Heme content of normal and porphyric cultured skin fibroblasts. Biochem Genet 1977;15:1061-1071
68. Bonkovsky HL, Tschudy DP, Weinbach EC. Porphyrin synthesis and mitochrondrial respiration in acute intermittent porphyric: studies using cultured human fibroblasts. J Lab Clin Med 1975;85:93-102
69. Barak Y, Arnon S, Wolach B, et al. Melas syndrome, peripheral neuropathy and cytochrome C-oxidase deficiency a case report and review of the literature. Isr J Mcd Sci 1995;31:224-229
70. DeMatteis F. Hepatic porphyrias caused by 2-allyl-2-isopropylacetamide, 3-5-deethoxycarbonyl-1,4-dihydrocollidine, griseofulvin and related compounds. In: DeMatteis F, Aldrige WN (eds): Heme and hemeproteins. Handbook of Experimental Pharmacology. Springer-Verlag, New York, 1978
71. Strand LJ, Felsher BF, Redeker AG, et al. Heme biosynthesis in intermittent acute porphyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta-aminolevulinic acid synthetase activity. Proc Natl Acad Sci USA 1970; 67:1315-1320